Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease

Movement Disorders

Volumn 29, Issue 14, 2014, Pages 1802-1808

  Siepel, Françoise J ^a   Brønnick, Kolbjørn S ^a,b   Booij, Jan ^c   Ravina, Bernard M ^d   Lebedev, Alexander V ^a   Pereira, Joana B ^e   Grüner, Renate ^f,g   Aarsland, Dag ^a,e,h  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF STAVANGER   (Norway)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^e KAROLINSKA INSTITUTE   (Sweden)

^f HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY OF BERGEN   (Norway)

^h AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cognitive impairment; Dopamine transporter; Parkinson's disease; SPECT; 123I FP CIT

Indexed keywords

2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; DOPAMINE; DOPAMINE TRANSPORTER; TROPANE DERIVATIVE;

ADULT; AGED; CLINICAL TRIAL; COGNITION DISORDERS; CORPUS STRIATUM; CROSS-SECTIONAL STUDY; DIAGNOSTIC USE; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROCEDURES; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COGNITION DISORDERS; CORPUS STRIATUM; CROSS-SECTIONAL STUDIES; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 84918553708     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26051     Document Type: Article

References (41)

1. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001;56:730-736.
2. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-199.
3. Braak H, Rub U, Del Tredici K. Cognitive decline correlates with neuropathological stage in Parkinson's disease. J Neurol Sci 2006;248:255-258.
4. Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010;75:1062-1069.
5. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006;21:1343-1349.
6. Yarnall AJ, Rochester L, Burn DJ. Mild cognitive impairment in Parkinson's disease. Age Ageing 2013;42:567-576.
7. 18F]fluorodopa positron emission tomographic study. Arch Neurol 2000;57:470-475.
8. Hirano S, Shinotoh H, Eidelberg D. Functional brain imaging of cognitive dysfunction in Parkinson's disease. J Neurol Neurosurg Psychiatry 2012;83:963-969.
9. Cools R. Dopaminergic control of the striatum for high-level cognition. Curr Opin Neurobiol 2011;21:402-407.
10. Narayanan NS, Rodnitzky RL, Uc EY. Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease. Rev Neurosci 2013;24:267-278.
11. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010;9:1200-1213.
12. 123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging 2009;37:443-450.
13. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003;18:1415-1423.
14. 123I]beta-CIT SPECT and prefrontal cognitive functions in Parkinson's disease. J Neural Transm 2000;107:303-319.
15. Duchesne N, Soucy JP, Masson H, Chouinard S, Bedard MA. Cognitive deficits and striatal dopaminergic denervation in Parkinson's disease: a single photon emission computed tomography study using 123iodine-beta-CIT in patients on and off levodopa. Clin Neuropharmacol 2002;25:216-224.
16. Nobili F, Campus C, Arnaldi D, et al. Cognitive-nigrostriatal relationships in de novo, drug-naive Parkinson's disease patients: a [I-123]FP-CIT SPECT study. Mov Disord 2010;25:35-43.
17. Polito C, Berti V, Ramat S, et al. Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson's disease. Neurobiol Aging 2012;33:206.e29-39.
18. Ekman U, Eriksson J, Forsgren L, Mo SJ, Riklund K, Nyberg L. Functional brain activity and presynaptic dopamine uptake in patients with Parkinson's disease and mild cognitive impairment: a cross-sectional study. Lancet Neurol 2012;11:679-687.
19. Parkinson Progression Marker I. The Parkinson Progression Marker Initiative (PPMI). Progr. Neurobiol 2011;95:629-635.
20. Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord 2007;22:41-47.
21. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-699.
22. Brandt J, Benedict RHB. Hopkins Verbal Learning Test-Revised. Odessa, FL: Psychological Assessment Resources 2001.
23. Benton AL, Varney NR, Hamsher KD. Visuospatial judgment. A clinical test. Arch Neurol 1978;35:364-367.
24. Pereira JB, Svenningsson P, Weintraub D, et al. Initial cognitive decline is associated with cortical thinning in early Parkinson disease. Neurology 2014;82:2017-2025.
25. 123I]FPCIT SPECT. J Nucl Med 1999;40:753-761.
26. 123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging 2013;40:213-227.
27. Hayes AF. Introduction to Mediation, Moderation, and Conditional Process Analysis: A Regression-Based Approach. New York: The Guilford Press; 2013.
28. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:175-191.
29. Levy G. The relationship of Parkinson disease with aging. Arch Neurol 2007;64:1242-1246.
30. Monchi O, Ko JH, Strafella AP. Striatal dopamine release during performance of executive functions: a [(11)C] raclopride PET study. Neuroimage 2006;33:907-912.
31. Marie RM, Barre L, Dupuy B, Viader F, Defer G, Baron JC. Relationships between striatal dopamine denervation and frontal executive tests in Parkinson's disease. Neurosci Lett 1999;260:77-80.
32. Cheesman AL, Barker RA, Lewis SJ, Robbins TW, Owen AM, Brooks DJ. Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease. J Neurol Neurosurg Psychiatry 2005;76:1204-1210.
33. Christopher L, Marras C, Duff-Canning S, et al. Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment. Brain 2014;137:565-575.
34. Jokinen P, Bruck A, Aalto S, Forsback S, Parkkola R, Rinne JO. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord 2009;15:88-93.
35. 18F]FDOPA. Psychiatry Res 2008;163:171-182.
36. Arnaldi D, Campus C, Ferrara M, et al. What predicts cognitive decline in de novo Parkinson's disease? Neurobiol Aging 2012;33:1127.e11-20.
37. Ravina B, Marek K, Eberly S, et al. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord 2012;27:1392-1397.
38. Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol 2012;11:697-707.
39. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009;132:2958-2969.
40. Bouchard TP, Malykhin N, Martin WR, et al. Age and dementia-associated atrophy predominates in the hippocampal head and amygdala in Parkinson's disease. Neurobiol Aging 2008;29:1027-1039.
41. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997;41:58-64.